Table 5.
Comparison between patients with high 2M-DBR and low 2M-DBR.
| High 2M-DBR Group (n = 25) | Low 2M-DBR Group (n = 20) | p Value | |
|---|---|---|---|
| Age (years, range) | 68.5 ± 8.47 | 72.8 ± 8.19 | 0.1018 |
| Gender (male/female) | 22/3 | 15/5 | 0.2226 |
| Body weight (<60kg/≥60kg) | 6/19 | 10/10 | 0.0702 |
| BSA (m2) | 1.76 ± 0.14 | 1.66 ± 0.18 | 0.0309 |
| Etiology (HBV vs. HCV vs. non-B non-C) | 5/8/12 | 1/8/11 | 0.3360 |
| TNM stage (III vs. IVA vs. IV B) | 9/3/13 | 7/5/8 | 0.4960 |
| BCLC stage (B vs. C) | 9/16 | 7/13 | 0.9445 |
| Treatment history (Naïve vs. recurrence) | 3/22 | 2/18 | 0.8320 |
| AST (IU/L) | 40.5 ± 19.9 | 49.0 ± 28.9 | 0.4172 |
| ALT (IU/L) | 27.0 ± 12.0 | 30.0 ± 18.8 | 0.9818 |
| Platelets (×104/μL) | 15.0 ± 7.01 | 14.7 ± 6.95 | 0.9272 |
| ALB (g/dL) | 3.63 ± 0.50 | 3.49 ± 0.35 | 0.1385 |
| T-Bil (mg/dL) | 0.84 ± 0.25 | 0.98 ± 0.43 | 0.2316 |
| PT (%) | 92.1 ± 15.2 | 96.3 ± 15.7 | 0.7975 |
| Child–Pugh score (5A vs. 6A vs. 7B) | 14/9/2 | 9/7/4 | 0.4804 |
| ALBI score | −2.33 ± 0.43 | −2.18 ± 0.35 | 0.2007 |
| mALBI grade (1 vs. 2a or 2b) | 9/16 | 2/18 | 0.0437 |
| BTR | 6.78 ± 2.00 | 4.97 ± 1.94 | 0.0222 |
| CONUT score | 3.12 ± 1.70 | 4.30 ± 1.71 | 0.0281 |
| FIB-4 index | 4.67 ± 4.20 | 5.80 ± 4.33 | 0.2217 |
| M2BPGi (cut-off index) | 2.21 ± 2.61 | 3.60 ± 3.09 | 0.0760 |
| Initial dose of lenvatinib(standard vs. reduced) | 19/6 | 10/10 | 0.0702 |
Values are presented as mean ± standard deviation (range) or number. Abbreviations: 2M-DBR, dose intensity/body surface area ratio at 60 days; BSA, body surface area; HBV, hepatitis B virus; HCV, hepatitis C virus; BCLC, Barcelona Clinic Liver Cancer; TACE, transarterial chemoembolization; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ALB, albumin; T-Bil, total bilirubin; PT, prothrombin time; ALBI, albumin-bilirubin; mALBI, modified ALBI; BTR, branched-chain amino acids tyrosine ratio; CONUT, Controlling Nutrition Status; FIB-4, Fibrosis-4; M2BPGi, Mac-2-binding protein glycosylation isomer.